Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Karo Bio starts Phase I study of diabetic drug
The Phase I program will start with single and multiple ascending doses given to healthy volunteers. The last part of the program will include multiple doses given to
The Phase I program will start with single and multiple ascending doses given to healthy volunteers. The last part of the program will include multiple doses given to
This licensing agreement gives AstraZeneca access to Oncomine Concepts Edition (OCM), a value-added product extension of Oncomine that combines nearly 7,000 proprietary cancer gene signatures with 11,000 gene,
Under the agreement, subject to the satisfaction of customary closing conditions, Pittsburgh-based PTI would be the surviving corporation in a merger with a subsidiary of Oracle. PTI would
The company expects to have data from this trial in the second half of 2008. This Phase II trial followed a positive Phase I study that demonstrated clinical
The primary objectives of this study will be to determine the antitumor activity of orally-administered MKC-1 in unresectable or metastatic pancreatic cancer patients who have failed at least
The results of this pilot study show that MIST-B04 presents a pharmacokinetic profile leading to a once daily dosing schedule compared to the three times daily immediate-release formulation
The results showed that treatment with Copaxone reduced the risk of developing clinically definite multiple sclerosis (CDMS) by 44% versus placebo, and prolonged the quartile time to disease
AzaSite was approved for bacterial conjunctivitis treatment by the FDA in April 2007, and was commercially launched in the US in August 2007 by Inspire Pharmaceuticals, AzaSite’s exclusive
Experts suggest that the increase in incidence of high blood pressure among children and adolescents is linked to the growing pediatric obesity epidemic. John Orloff, senior vice president,
BioMarin has executed a research and option agreement with Igan Biosciences for intellectual property covering IgA proteases for treating IgA nephropathy. IgA proteases have been shown to cleave